Bio/Pharma Business

Takeda expands its global and therapy base with announced acquisition of Shire.

A skilled workforce is needed to deliver on technology’s promising medical advances.

LNC Therapeutics has appointed a new CEO and is strengthening its R&D for gut microbiome-based drugs.

The transaction is part of Merck KGaA’s strategy to actively shape its product portfolio and focus on innovation-driven business.

Global investment firm Advent to acquire and invest in Sanofi’s European generics business, Zentiva, to boost its position in European market.

Johnson & Johnson’s Janssen partners with Bristol-Myers Squibb to advance next-generation therapies for cardiovascular diseases.

The acquisition is expected to accelerate progress towards personalized cancer healthcare.

Roche has acquired a program to develop regenerative therapies for multiple sclerosis.

Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.

Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.

The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.

Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.

Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.

New therapies and tighter budgets challenge bio/pharma to think outside the industry.

The company’s close communication with customers has enabled it to bring advanced pipetting products to market.

The acquisition strengthens Celgene’s position in the global cellular immunotherapy space.

The companies will co-develop and co-promote a CAR T cell therapy in the United States.

Takeda is considering approaching Shire with a possible offer.

In a $13-billion transaction, GSK will purchase Novartis’ share of the Consumer Healthcare Joint Venture.

Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.

The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.

Helsinn will acquire the global rights to Valchlor/Ledaga (mechlorethamine/chlormethine), a topical skin-cancer drug, from Actelion Pharmaceuticals.

Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.

The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.

Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.

With minimal damage to its manufacturing plant in Humacao, Puerto Rico, Colorcon has been able to restore full operations.

The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.

The acquisition strengthens an already existing collaboration between the companies to advance clinical development of therapies across multiple drug categories.

Through its Janssen pharmaceutical companies, Johnson & Johnson, has partnered with Theravance to develop and commercialize a therapeutic for inflammatory bowel diseases.

Amgen plans to invest approximately $300 million in a new biomanufacturing plant in the United States.